![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
The collaboration aims to develop an autoinjector for clinical and potential subsequent commercial supply of MoonLake’s Nanobody® M1095 (sonelokimab) by using SHL Medical's market-proven Molly® modular platform technology.
Lead Product(s): Sonelokimab,Adalimumab
Therapeutic Area: Immunology Product Name: M1095
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: MoonLake Immunotherapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 03, 2023